Innate lymphoid cells (ILCs) are important for mucosal immunity. The intestine harbors all ILC subsets, but how these cells are balanced to achieve immune homeostasis and mount appropriate responses during infection remains elusive. Here, we show that aryl hydrocarbon receptor (Ahr) expression in the gut regulates ILC balance. Among ILCs, Ahr is most highly expressed by gut ILC2s and controls chromatin accessibility at the Ahr locus via positive feedback. Ahr signaling suppresses Gfi1 transcription-factormediated expression of the interleukin-33 (IL-33) receptor ST2 in ILC2s and expression of ILC2 effector molecules IL-5, IL-13, and amphiregulin in a cellintrinsic manner. Ablation of Ahr enhances antihelminth immunity in the gut, whereas genetic or pharmacological activation of Ahr suppresses ILC2 function but enhances ILC3 maintenance to protect the host from Citrobacter rodentium infection. Thus, the host regulates the gut ILC2-ILC3 balance by engaging the Ahr pathway to mount appropriate immunity against various pathogens.
In Brief
The aryl hydrocarbon receptor (Ahr) promotes ILC3 maintenance and function. Li et al. report that Ahr restricts intestinal ILC2 function in a cell-intrinsic manner, suggesting a central role for gut adaptation of Ahr expression in regulating the ILC2-ILC3 balance.
INTRODUCTION
Innate lymphoid cells (ILCs) represent an emerging family of cell types, including natural killer (NK) cells (which express both transcription factors T-bet and Eomes), group 1 ILCs (ILC1s; which express T-bet but not Eomes), group 2 ILCs (ILC2s; which express transcription factor GATA3), and group 3 ILCs (ILC3s; which express transcription factor RORgt) (Artis and Spits, 2015) . ILCs play important roles in tissue remodeling and innate immunity, particularly at barrier surfaces (Ebbo et al., 2017; Klose and Artis, 2016) . Various tissues contain distinct ILC subsets. For instance, the liver is enriched with ILC1s; the lung contains ILC2s in mice under the steady state despite the existence of other ILCs in humans; in contrast, the mouse gut harbors all three major ILC subsets (Li et al., 2018; Simoni and Newell, 2018) . It is unknown how various ILCs are kept in balance for gut immune homeostasis and how the host orchestrates a diverse population of ILCs to control infection and inflammation.
The aryl hydrocarbon receptor (Ahr) is a ligand-dependent environmental sensor, and its transcriptional activity requires ligand-induced nuclear translocation and dimerization with its partner, the aryl hydrocarbon receptor nuclear translocator (ARNT) (Cella and Colonna, 2015) . Best known for sensing environmental toxins (e.g., 2,3,7,8-tetrachloro-dibenzo-p-dioxin), Ahr can also respond to endogenous ligands generated from host cells, diet, and microbiota (Zhou, 2016) . Ahr is expressed in barrier tissues (e.g., the gut and skin) by immune cells, such as lymphocytes, and by tissue structural cells, such as epithelial and stromal cells (Stockinger et al., 2014) . The presence of Ahrexpressing cells in those locations could represent a mechanism of tissue adaptation by allowing the host to readily respond to external environmental changes. Consistent with this notion, regulatory T (Treg) cells in the gut express higher amounts of Ahr than those in other lymphoid or non-lymphoid tissues (Ye et al., 2017) .
Recent studies have shown that Ahr plays important roles in regulating ILCs. For example, Ahr is required for liver-resident ILC1 maintenance (Zhang et al., 2016) . Ahr is also essential for ILC3 maintenance and function (Kiss et al., 2011; Lee et al., 2011; Qiu et al., 2012) . Ahr-expressing ILC3s regulate intestinal T helper 17 (Th17) cells and microbiota and thus gut inflammation (Hepworth et al., 2013; Qiu et al., 2013) . Mechanistically, Ahr works cooperatively with transcription factors RORgt and STAT3 to induce interleukin-22 (IL-22) for anti-bacterial immunity (Guo et al., 2014; Qiu et al., 2012) . Ahr activity in ILC3s can be inhibited by a zinc-finger transcription factor, Ikaros, via a mechanism involving disruption of the Ahr-ARNT complex (Li et al., 2016) . Despite the progress of our understanding of Ahr in ILCs, how Ahr expression is regulated in ILCs and its function in other ILCs (e.g., ILC2s) are unknown. In this study, we show that among various ILCs in the gut, Ahr is expressed at the highest level by ILC2s. Specific chromatin events mark a tissue adaptation of Ahr expression in gut ILC2s. In contrast to its function in promoting ILC3 maintenance, Ahr suppresses ILC2 function, thus representing a critical node of regulation of the ILC balance for gut immunity against various pathogenic infections.
RESULTS

Ahr Is Expressed Specifically in Gut-Resident ILC2s
To gain insight into the role of Ahr in ILCs, we asked how Ahr is expressed in various ILC lineages. Compared with ILC progenitors (CHILP and ILC2P) and other mature ILCs (including ILC3s), gut ILC2s express the highest amounts of Ahr protein and mRNA ( Figures 1A, 1B , S1A, and S1B). We have recently developed an Ahr-knockin mouse model, Ahr dCAIR/+ , which expresses a constitutively active form of Ahr (CA-Ahr) and IRES-GFP from the endogenous Ahr locus ( Figure S1C ) (Ye et al., 2017 Figures 1C-1E and S1D). Ahr expression in ILC2s was not significantly changed between germ-free (GF) mice and specific-pathogen-free (SPF) mice ( Figure S1E ), suggesting a dispensable role for the microbiota in Ahr expression by gut ILC2s. Despite the expression of Ahr, ILC2s did not make IL-22 (data not shown), presumably because of a lack of RORgt and/or STAT3, which work cooperatively with Ahr and are essential for Il22 transcriptional induction in ILC3s (Guo et al., 2014; Qiu et al., 2012) . Transforming growth factor b (TGF-b) promotes Ahr expression in CD4 + T cells (Kimura et al., 2008; Quintana et al., 2008; Veldhoen et al., 2008) and has been shown to regulate the differentiation and function of tissue-resident ILCs (Cortez et al., 2016; Denney et al., 2015) . Because TGF-b is enriched in the gut, we sought to examine whether TGF-b is responsible for the high Ahr expression in gut ILC2s. Sorted gut ILC2s gradually lost Ahr expression in vitro with or without TGF-b (Figures S1F and S1G). Treatment of TGF-b did not induce Ahr expression in ILC2s that had lost Ahr after in vitro culture (Figures S1H and S1I) . Together, these data suggest that in vivo gut milieu supports Ahr expression in ILC2s, and despite its abundance in the gut, TGF-b itself was not sufficient to sustain and/or induce the expression of Ahr in ILC2s in the in vitro culture system.
The Ahr Locus in Gut ILC2s Has a Unique Chromatin Structure To determine the potential mechanism underlying the gut-specific expression of Ahr in ILCs, we analyzed chromatin accessibility at the Ahr locus by using the assay for transposase-accessible chromatin using sequencing (ATAC-seq) data generated from various ILC lineages (Shih et al., 2016) , and several chromatin features at the Ahr locus emerged. Despite various levels of expression of Ahr in ILC subsets and Treg cells (Figures 1A, 1B, and S2A) , the chromatin conformation was generally open at the transcription start site of Ahr ( Figure S2B ). At least six regions (boxed in red) identified at the Ahr locus showed unique gut-ILC2-specific ATAC peaks, i.e., peak 1 (À8 kb), peak 2 (+7.6 kb), peak 3 (+14 kb), peak 4 (+24 kb), peak 5 (+41 kb), and peak 6 (+54 kb), indicating open chromatin ( Figure S2B ). These peaks were evident neither in other ILCs (NK cells, ILC1s, or ILC3s) nor in lung ILC2s ( Figure S2B ). Gut Treg cells also expressed higher amounts of Ahr than Treg cells in the lymphoid organs (e.g., thymus, spleen, and lymph nodes) and other tissue-resident Treg cells in the lung, fat, skin, and liver (Ye et al., 2017) . However, these gut-ILC2-specific open-chromatin events at the Ahr locus were mostly absent in gut Treg cells ( Figure S2B ). Together, these data suggest that these chromatin-accessible regions could function as transcriptional enhancers and are responsible for tissue-specific and/or high expression of Ahr by ILC2s in the gut.
Ahr Regulates Gut-Specific Chromatin Events at the Ahr Locus
We next sought to determine whether deletion of Ahr could affect chromatin accessibility at the Ahr locus. To exclude the confounding impact on the ILC2 phenotypes by the adaptive immune system (Halim et al., 2016; Oliphant et al., 2014) , we sorted gut ILC2s (Lin À KLRG1 + CD90 + ) ( Figure S2C ) (Pelly et al., 2016) from Ahr
ATAC-seq conducted with the sorted intestinal ILC2s revealed that without prominent changes of other gut ILC2-specific peaks, certain peaks, including peaks 3 and 6, were markedly decreased in the absence of Ahr, suggesting that Ahr regulates its own locus chromatin accessibility ( Figure 1F ). Consistent with unchanged Ahr expression ( Figure S1E ), the gut-ILC2-specific chromatin events at the Ahr locus (e.g., peak 6) were minimally affected (without statistical significance) in GF mice compared with SPF mice, as revealed by ATAC-seq analysis ( Figure S2D ). Transcription factors can auto-regulate their transcription by binding to their own locus (e.g., the promoter and/or enhancers). To test the potential self-regulation of Ahr, we conducted chromatin immunoprecipitation (ChIP) of Ahr with ILC2s sorted from Ahr À/À or Ahr +/+ mice. Among two Ahr-dependent ATACseq peaks, peak 6 (located around 54 kb downstream of the transcription start site) showed enrichment of Ahr ( Figure 1G ), suggesting a differential requirement for Ahr binding in chromatin accessibility. Together, these data show that Ahr regulates chromatin remodeling at its own locus in gut ILC2s.
Cooperative Action of Ahr and Gfi1 Promotes Ahr Transcription in ILC2s
Through in silico motif analysis of the peak 6 region, we identified the evolutionarily conserved consensus sequences for Gfi1 and Gata3, transcription factors that play important roles in ILC2 development and function (data not shown). Recruitment of Gfi1 and GATA3 to peak 6 was further confirmed by a previously published ILC2 ChIP-sequencing (ChIP-seq) analysis (Spooner et al., 2013; Zhong et al., 2016) (Figure 1F ). These data prompted us to assess the potential synergy between Ahr and other key ILC2 regulators, which could potentiate Ahr transcription. To this end, we performed Gfi1 and GATA3 ChIP experiments with sorted large intestinal ILC2s from Ahr À/À or Ahr +/+ littermate mice. Strikingly, Ahr deficiency in ILC2s significantly reduced the recruitment of Gfi1 and GATA3 to the peak 6 region ( Figures  1H and 1I ), suggesting that binding of Gfi1 and GATA3 to the Ahr locus is dependent on Ahr and is presumably facilitated by Ahrdirected permissive chromatin changes. In accordance with these binding events at the Ahr locus, Ahr-deficient ILC2s and Gfi1-deficient ILC2s showed reduced Ahr transcription ( Figures  1F, 1J , and S2E) (Spooner et al., 2013) , whereas deletion of GATA3 had a minimal effect on Ahr expression in ILC2s (Figure S2F ) (Yagi et al., 2014) . In addition, Ahr-deficient Treg cells showed no detectable reduction of Ahr mRNA ( Figure S2G ). Together, these data suggest that Ahr might cooperate with Gfi1 to promote its own transcription in ILC2s.
Ahr Deficiency Alters the ILC2 Transcriptional Program
To gain more insight into the regulation of the ILC2 transcriptional program by Ahr, we performed genome-wide analysis of mRNA expression with RNA-sequencing (RNA-seq) data of gut ILC2s. Gene expression analysis identified 424 significantly changed genes (q value % 0.05, fold change R 1.5) out of 11,286 expressed genes (fragments per kilobase of transcript per million mapped reads [FPKM] R 1) in the Ahr-deficient ILC2s; among these genes, 278 were upregulated and 146 were downregulated in the small intestine of Ahr À/À Rag1 À/À mice ( Figure 2A ). Large intestinal ILC2s that lacked Ahr showed 168 significantly changed genes out of 11,458 expressed genes, among which 109 were upregulated and 59 were downregulated ( Figure 2A ). Despite an overlapping set of differentially expressed genes, unique genes were found to be regulated by Ahr in small or large intestinal ILC2s, consistent with the distinct features of these two organs ( Figure 2B ). When cross-referencing to the previously published 32 ILC2-characteristic 
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(H) Annotation of differentially expressed ATAC-seq peak locations in ILC2s and ILC3s from the SI and LI of littermate Ahr
See also Figures S3 and S4.
protein-coding genes whose expression is at least 4-fold higher than that in other ILC subsets in the small intestines (Robinette et al., 2015) , we found differential regulation of these genes (16 out of 32 for the small intestine and 12 out of 32 for the large intestine) by Ahr ( Figures 2C and 2D ). Together, these data suggest that Ahr regulates a broader set of ILC2 gene transcription that is not limited to the ILC2 signature program. We further determined the impact of Ahr on the expression of genes that have been implicated in the literature to play an important role in transcriptional control of ILC2s (Li et al., 2018; Sonnenberg and Artis, 2015) . In the small intestine, Gfi1, Tcf7, Nfil3, Id2, Ets1, and Tox expression was increased in Ahr-deficient ILC2s (q value % 0.05), whereas Gata3, Rora, Bcl11b, and Ehmt2 (G9a) expression was not significantly changed ( Figure 2E ). In the large intestine, Gfi1 was upregulated (q value % 0.05) in the absence of Ahr, whereas the other key regulators mostly remained statistically unchanged or downregulated (e.g., Tox) ( Figure 2E ). Together, these data suggest that Ahr selectively regulates a subset of ILC2-related genes in the gut.
Genes that were increased in the small intestines of Ahr À/À Rag1 À/À mice showed enrichment in pathways involved in cytokine-cytokine-receptor interaction, the chemokine signaling pathway, and the T cell receptor signaling pathway ( Figure S3A ). Downregulated genes showed enrichment in pathways involved in adherens junctions, Jak-STAT signaling, tight junctions, and lysosome and lysine degradation signaling pathways ( Figure S3A ). The cytokine-cytokine-receptor interaction pathway also showed downregulation in Ahr-deficient ILC2s ( Figure S3A ), most likely from the downregulation of IL-2 in Ahr-deficient ILC2s (data not shown). Together, these data suggest that Ahr targets various signaling pathways to regulate ILC2 gene transcription.
Ahr Regulates Chromatin Accessibility at Select Gene Loci in ILCs
Globally, ATAC-seq peaks did not change between Ahr-deficient and Ahr-sufficient ILC2s or ILC3s sorted from Ahr
and Ahr +/+ Rag1 À/À littermate mice ( Figure S3B-S3E) ; however, loss of Ahr did affect a number of specific peaks in ILC2s (around 1.5% of total peaks for the small intestine and 1.4% of total peaks for the large intestine) and ILC3s (around 7.4% of total peaks for the small intestine and 6.6% of total peaks for the large intestine) ( Figure S3F ), indicating that Ahr does not function as a general chromatin remodeler in ILCs but instead regulates selective chromatin events in the genome. The differentially expressed genes in ILCs correlated with the changes in ATACseq peak signals (e.g., Il1rl1 for ILC2s and Il22 for ILC3s) (Figures 2F and S3F) . Chromatin changes observed at the Ahr and Il1rl1 loci in Ahr-deficient ILC2s on the Rag1 À/À background were similar to those on the C57BL/6 background ( Figures S4A and  S4B ). The location of ATAC-seq peaks in the genome were mostly unchanged between Ahr À/À and Ahr +/+ ILC2s or ILC3s, and most peaks were located in the promoters (18%-23%), introns (39%-41%), and intergenic regions (29%-37%) (Figure 2G) . However, the differentially regulated peaks were preferentially located in the introns (48%-51%) or intergenic regions (41%-44%), but not the promoters (3%-6%), of ILCs ( Figure 2H ), suggesting a critical role for Ahr in regulating ILC distal regulatory gene elements (e.g., enhancers).
Ahr Suppresses ILC2 Function
In contrast to its positive role in promoting ILC3s (Kiss et al., 2011; Lee et al., 2011; Qiu et al., 2012) Figure S5C ) despite minimal expression of Ahr in ILC2P ( Figure S1A ), suggesting a cell-extrinsic mechanism of regulation. Consistent with RNA-seq data, ST2 (encoded by Il1rl1), an IL-33 receptor that is a key cytokine for promoting ILC2 responses (Artis and Spits, 2015) , and Il1rl1 mRNA were upregulated in Ahr À/À ILC2s ( Figures 3C, 3D , and S5D). Ahr À/À ILC2s produced more IL-5 and IL-13 ( Figures 3E-3G) , indicating enhanced ILC2 function in the absence of Ahr. Besides type 2 cytokines, ILC2s have been shown to secrete amphiregulin (Areg) (Monticelli et al., 2015) . In addition to increasing expression of IL-5 and IL-13, lack of Ahr also led to increased overall Areg expression in ILC2s ( Figures S5E, S5F , S5H, S5K, and S5M). However, ILC2s that produced Areg only, but not IL-5 or IL-13, were unchanged in the absence of Ahr . Consistent with the Ahr-deficient mice on the C57BL/6 background, enhanced ILC2 frequency, number, ST2 expression, and production of IL-5 and IL-13 were observed in the gut of Ahr Figures 3H-3N (Figures S6A-S6E ), whereas ST2 + ILC2s and production of IL-5 and IL-13 showed significant upregulation ( Figures S6C and S6F-S6I ).
To further corroborate these data and determine the role of Ahr in ILCs in a cell-intrinsic manner, we performed a mixedbone-marrow transfer experiment. Specifically, bone marrow from Ahr À/À (CD45.2/CD45.2) and wild-type (CD45.1/CD45.1)
mice was mixed at a 1:1 ratio and transferred into Rag2 À/À Il2rg À/À mice ( Figure S6J ). ILCs were isolated from the small and large intestines of the bone-marrow-chimeric mice and stained with congenic markers to distinguish their origins ( Figure S6K ). Consistent with the reported role of Ahr in ILC3s (Kiss et al., 2011; Lee et al., 2011; Qiu et al., 2012) , marked decreases in Ahr À/À (CD45.2/CD45.2) ILC3s were observed in the intestines ( Figures S6L and S6M ). Despite reduced ILC2P in the bone marrow of Ahr-deficient mice (Figure S5C) , comparable mature ILC2s were differentiated in the gut ( Figures S6L and S6M ). In addition, ILC2s derived from Ahr À/À bone marrow expressed more ST2 and IL-13 than those from wild-type bone marrow ( Figures S6N-S6P 
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À/À mice) was most likely due to a cell-extrinsic mechanism, at least in part by the lack of ILC3s; however, the upregulation of ST2, IL-5, and IL-13 expression in the absence of Ahr was ILC2 intrinsic. Of note, Ahr f/f Vav1-cre mice also showed a trend toward increased ILC2 frequency and number ( Figures S6D and S6E) , consistent with ILC3 deficiency in these mice.
To further determine the regulation of ILC2 function by Ahr, we equally mixed sorted mature ILC2s from the small intestine of wild-type (CD45.1/CD45.1) or Ahr À/À (CD45.2/CD45.2) mice and transferred them into Rag2 Figure 4A ). In the presence of wild-type ILC2s, the Ahr-deficient ILC2s still expressed more ST2, IL-5, and IL-13, supporting an ILC2-intrinsic role of Ahr ( Figures 4A-4E ).
ILC2s are the major producers of IL-5 in the gut, and Il5
RFP-cre mice have been used for the deletion of genes in ILC2s See also Figure S5 . . To validate the cell-intrinsic role of Ahr in ILC2s, we generated Ahr f/f Il5 RFP-Cre mice. RFP + ILC2s showed efficient deletion of Ahr ( Figure 4F ). ST2 expression and IL-5 and IL-13 production were higher in the RFP + ILC2s of Ahr Figure 4L ). Compared with non-transduced cells, transduced ILC2s with the expression of Cre and thus deletion of Ahr had increased expression of ST2 and cytokines IL-5 and IL-13 ( Figures 4L and 4M) . Collectively, these data demonstrate a cell-intrinsic role for Ahr in regulating ILC2 function. in Ahr À/À Il33 À/À mice was still higher than that in Il33 À/À mice (Figures 5D-5F ). Together, these data suggest that enhancement of ILC2 function in Ahr À/À mice is at least partly dependent on the IL-33-ST2 pathway. Gfi1 has been shown to regulate ST2 expression in ILC2s through direct binding to the Il1rl1 (ST2) locus (Spooner et al., 2013) . Consistent with RNA-seq data, the expression of Gfi1 mRNA was increased in Ahr À/À ILC2s ( Figure 5G ). Accordingly, a ChIP-PCR assay detected more recruitment of Gfi1 to two binding sites of the Il1rl1 locus in Ahr-deficient ILC2s ( Figures  5H and 5I) . Enrichment of Ahr was observed at the À2 kb site but not À11 kb upstream of the transcription start site at the Il1rl1 locus ( Figure 5J ), suggesting that Ahr could directly suppress ST2 transcription.
Ahr Ablation Enhances Anti-helminth Immunity
Type 2 immunity is important for the host to control worm infection (Pelly et al., 2016; Schneider et al., 2018) . To determine the role of Ahr in anti-helminth immunity, we infected Ahr (Figures 6C and 6D) .
including a marked increase in ILC2 number and higher IL-5 and IL-13 expression, consistent with elevated eosinophils (Figures 6E-6H ). In addition, expression of resistin-like molecule b (RELM-b), which has been shown to be involved in protection against infection by parasitic helminth (Artis et al., 2004) , was upregulated in the gut of Ahr Figure 6I ). It has been shown that a lack of IL-22 impairs worm expulsion upon Nippostrongylus brasiliensis and Trichuris muris infections (Turner et al., 2013) . Thus, the defect of IL-22-producing ILC3s in Ahr-deficient mice might compromise the ILC2-mediated worm clearance. To validate the cell-intrinsic function of ILC2s in anti-parasite immunity, we transferred the Ahr-sufficient or -deficient ILC2s into Rag2 À/À Il2rg À/À mice and infected the recipients with H. polygyrus bakeri ( Figure 6J ). Compared with those receiving Ahr-sufficient ILC2s, Rag2 À/À Il2rg À/À mice receiving Ahr-deficient ILC2s had enhanced anti-helminth immunity with fewer worms and eggs ( Figures 6K-6Q ). Together, these data demonstrate that, as in the steady state, Ahr deficiency results in enhanced ILC2 function during helminth infection to enhance protective immunity in the gut.
Gain of Function of Ahr Suppresses ILC2s but Enhances
ILC3s to Better Control C. rodentium Infection Expression of AhrDPAS-B (CA-Ahr) in mice increased the frequency and number of gut RORgt + ILC3s (Figures 7A-7C ).
Further analysis of ILC2s in Ahr +/+ and Ahr dCAIR/+ mice showed that CA-Ahr suppressed ILC2 numbers and ST2 expression (Figures 7D-7G) . Similarly, Ahr activation by treatment with the ligand 5,11-dihydroindolo[3,2-b]carbazole-6-carboxaldehyde (FICZ) led to downregulation of ILC2s and their ST2 expression ( Figures S7G and S7H) . The modest ILC2 suppression by Ahr activation via gain-of-function approaches is presumably due to activation of Ahr by endogenous ligands that are already abundantly present in the host. Consistent with this notion, mice fed an Ahr-ligand-depleted diet (AIN-76A) showed a minimal impact on Ahr expression ( Figure S7I ) or ST2 + ILC2s in the gut ( Figures S7J and S7K) . Together, these data suggest that Ahr activation regulates the ILC2-ILC3 balance in the gut by suppressing ILC2s while promoting ILC3s. We and others have shown that Ahr expression by RORgt + ILC3s is necessary for their function to control mucosal infection of C. rodentium (Kiss et al., 2011; Lee et al., 2011; Qiu et al., 2012) . However, it is unknown whether Ahr expression in RORgt + cells is sufficient for the host to control this bacterial infection.
To this end, we developed Ahr CAIR/CAIR Rorc-cre mice, which express CA-Ahr only in RORgt + cells but not in other cell types (Figure S7L) . Ahr CAIR/CAIR mice phenocopied Ahr À/À mice and had a marked reduction of IL-22 + ILC3s (Ye et al., 2017) . However, the IL-22 + ILC3s of Ahr CAIR/CAIR Rorc-cre mice were similar to those of Ahr-sufficient mice ( Figure S7M ). When inoculated with C. rodentium, Ahr CAIR/CAIR mice could not control the bacteria in the gut, resulting in a progressive loss of body weight and death at day 9 of the infection ( Figure 7H and data not shown), See also Figure S7 .
consistent with a compromised ILC3 compartment. Strikingly, compared with Ahr CAIR/CAIR mice, Ahr CAIR/CAIR Rorc-cre mice were completely protected from C. rodentium infection, as revealed by less weight loss and a reduced bacterial load ( Figures  7H and 7I ). These data show that CA-Ahr expression in RORgt + cells is sufficient to mount protective ILC3 immunity against mucosal bacteria, demonstrating the key role of Ahr in regulating the ILC2-ILC3 balance and gut immunity.
DISCUSSION
The molecular mechanisms underlying the balance of ILC subsets in tissues are poorly understood. Here, we have shown that the expression of Ahr in gut ILCs represents an adaptation to external environment and is essential for intestinal immunity through regulation of the ILC2-ILC3 balance. Previous studies have shown that enhancer landscapes characterizing T cell lineages are pre-established and strongly influenced by environmental stimuli (Samstein et al., 2012; Shih et al., 2016; Xu and Smale, 2012) . We hypothesized that unique chromatin events (enhancers) are specified in gut ILC2s by environmental cues and are responsible for promoting tissue-specific Ahr expression in gut ILC2s. We speculated that one candidate of such stimuli would be the microbiota, which are abundantly present in the gut. The fact that, compared with gut ILC2s from SPF mice, gut ILC2s from GF mice had minimal differences in chromatin remodeling at the Ahr locus and unaltered expression of Ahr supports a model in which the microbiota might play a dispensable role for Ahr transcription in ILC2s, consistent with the microbiota-independent mechanism of Ahr expression in gut Treg cells (Ye et al., 2017) . Our data also suggest that deprivation of Ahr dietary ligand has a minimal or modest impact on Ahr expression or activity in ILC2s. Together, these data suggest that a complex interaction among microbiota, diet, and probably other unidentified environmental factors in the gut could specify Ahr expression in intestinal immune cells.
Among the gut-ILC2-specific chromatin events at the Ahr locus, the remodeling of peak 6 was dependent on Ahr, indicating that Ahr facilitates its own gene chromatin accessibility. Despite high expression of Ahr in gut Treg cells (Ye et al., 2017) , peak 6 was absent at the Ahr locus, and accordingly the transcription of Ahr was unaffected in Ahr-deficient Treg cells. These data support a cell-type-specific positive-feedback role of Ahr in its own transcription in ILC2s. Our attempt to determine the role of peak 6 as an enhancer in the standard reporter assay by using transient transfection did not yield conclusive data, consistent with the fact that its function in chromatin remodeling is presumably not involved in transient-transfection assays (Zhou et al., 2007) . Thus, the function of peak 6 needs to be studied at an organismal level by the generation of mice with a mutation in this element and subsequent evaluation of immune responses (e.g., ILC2 compartment) under steady-state physiological conditions and in disease.
Gfi1 is a positive regulator of ILC2s (e.g., it promotes ST2 expression) (Spooner et al., 2013) . However, the observation that Gfi1 binds to peak 6 and promotes the expression of Ahr, a negative regulator of ILC2s, suggests a self-limiting mechanism to prevent exuberant ILC2 responses. Co-occupancy of Ahr and Gfi1 at the Il1rl1 promoter and increased Gfi1 expression and recruitment to the Il1rl1 promoter in Ahr-deficient ILC2s favor a model where Ahr keeps the ILC2 effector functions in check by suppressing the Gfi1-ST2 pathway, e.g., through the counteraction of Gfi1 at the Il1rl1 promoter.
Ablation of the IL-33-ST2 pathway has been shown to relieve experimental colitis, including the 2,4,6-trinitrobenzenesulfonicacid-and dextran-sulfate-sodium-induced colitis models in mice (Sedhom et al., 2013; Zhu et al., 2015) . Consistently, increased amounts of IL-33 and soluble ST2 have been shown in the colons of patients with inflammatory bowel disease (Pastorelli et al., 2010) , in line with the proinflammatory nature of type 2 immunity (e.g., IL-13) (Neurath, 2014) . However, a recent report has shown that the ILC2-associated effector molecule Areg participates in tissue repair in the gut (Monticelli et al., 2015) . ILC2s can also express IL-9 to promote epithelial cell maintenance in the lung (Mohapatra et al., 2016 (Colonna, 2018) . Lack of Bcl11b in ILC2s leads to loss of ILC2 functions but a gain of ILC3 features (Califano et al., 2015) . Given the role of Ahr in regulating ILC3 maintenance, it remains to be determined whether Ahr deficiency could convey the plasticity of ILC3s; however, this hypothesis needs to be carefully tested, e.g., through a fate-mapping genetic approach.
Genetic ablation of Ahr enhanced gut ILC2 function, consistent with enhanced immunity to adult H. polygyrus bakeri infection. Whether Ahr plays a similar role in other helminth infections remains to be determined. Ahr deficiency has been shown to cause compromised immunity against C. rodentium as a result of a loss of IL-22 + ILC3s (Kiss et al., 2011; Lee et al., 2011; Qiu et al., 2012) . Strikingly, Ahr expression in RORgt + cells alone is sufficient to maintain a functional ILC3 compartment and control C. rodentium infection. Because Ahr plays a differential role in various immune cells, pharmacological modulation of Ahr expression and/or activity could affect host immunity in a complex manner. Inhibition of Ahr promotes ILC2s that are beneficial for the host to mount an efficient immunity against worm infection but could also contribute to type-2-associated gut inflammation, such as ulcerative colitis and food allergy (Neurath, 2014; Stefka et al., 2014; Tordesillas et al., 2017) . On the other hand, Ahr activation could promote anti-bacterial immunity through enhancement of ILC3s and control autoimmunity by promoting Treg cell functions (Gutié rrez-Vá zquez and Quintana, 2018; Zhou, 2016) .
Although Ahr is expressed highly in mouse gut ILC2s, it remains to be determined whether this expression pattern is also evident in humans. Specifically, careful comparison of Ahr expression in ILCs among different human tissues is needed. Published high-throughput single-cell sequencing data show the existence of Ahr in human tonsil ILC2s; however, the level of its expression is lower than that in tonsil ILC3s (Bjö rklund et al., 2016) . In addition, Ahr mRNA is detectable in ILC2s from human peripheral-blood mononuclear cells, and TNF-like ligand 1A (TL1A) together with IL-25 and IL-33 can upregulate Ahr transcription in these cells (Lim et al., 2016) . Thus, future efforts are needed to elucidate the molecular mechanisms by which Ahr is expressed in different tissue milieu under the steady state and/or during inflammation. Understanding how Ahr regulates the gut ILC balance could provide new therapeutic opportunities in disease treatment and/or prevention.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: In Vivo Ahr Ligand Treatment Six-day-old C57BL/6 wild-type littermate mice were treated with FICZ (0.5 mg/day) by intraperitoneal injection for 7 days. DMSO was used as a vehicle control.
Ahr Ligand Deficient Diet Treatment
Two females from the same trio-breeding cage (one male and two females) dropped pups at the same time and were separated into individual cages with the pups. Then the nursing dams were fed with the Ahr ligand-deficient diet (AIN-76A, Envigo) or normal control diet (7912, Envigo) for 4 weeks before the analysis.
Bone Marrow Transfer
Bone marrow from Ahr À/À (CD45.2/CD45.2) and wild-type (CD45.1/CD45.1) mice were mixed at 1:1 ratio, and 4 3 10 6 cells in total were intravenously injected into Rag2
Il2rg
À/À mice irradiated at 550 rads twice with 5 hr interval. Recipient mice were treated with antibiotics (sulfamethoxazole and trimethoprim suspension, Hi-Tech Pharmacal) for 2 weeks after injection and were analyzed 8 weeks after transfer.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Methods
Unless otherwise noted, statistical analysis was performed with the unpaired two-tailed Student's t test on individual biological samples with GraphPad Prism. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-sequencing and ATAC-sequencing data files reported in this paper is GEO: GSE119461. The accession number for the ChIP-seq of GATA3 in ILC2s is GEO: GSE71198 (Yagi et al., 2014) . The accession number for the RNAseq of GATA3-deficient ILC2s is GEO: GSE47851 (Zhong et al., 2016) . The accession number for the ChIP-seq of Gfi1 in ILC2s is GEO: GSE50806, and the accession number for the microarray of Gfi1-deficient ILC2s is GEO: GSE45621 (Spooner et al., 2013) . The accession number for the ATAC-seq of hematopoietic progenitors and ILCs is GEO: GSE77695 (Shih et al., 2016) .
